A review of GHK-Cu s wound healing and skin regeneration research by Pickart and Margolina (2018), highlighted the importance of sustained application for achieving the full range of GHK-Cu s documented biological effects
These findings suggest that while FOXO4 is involved in the senescence pathway, it also plays a role in maintaining the viability of senescent Leydig cells by suppressing their apoptotic response, which could contribute to the accumulation of senescent cells [1]
Research Articles on Delta Sleep-Inducing Peptide (DSIP)
Over several weeks, patterns emerge that guide optimization
Weight loss by timeframe Month 1-2 (initial titration): 5-10 lbs lost Lower doses, body adapting Some appetite suppression Establishing habits Month 3-4 (dose escalation): 10-20 lbs total lost Significant appetite reduction Noticeable changes Plateau possible, keep titrating Month 5-8 (approaching maintenance dose): 20-35 lbs total lost Near or at full dose Maximum appetite suppression Consistent weekly loss (1-3 lbs) Month 9-12 (maintenance dose): 30-50 lbs total lost Full dose combination Continued steady loss Body composition improving Month 12-18 (long-term): 40-60+ lbs total lost (or 15-25% body weight) Exceptional responders: 60-80 lbs Weight stabilizing Focus shifts to maintenance Individual variation: Starting weight matters (higher = more absolute loss) Metabolism, activity level, diet affect results Some lose faster, some slower Consistency most important Comparison to semaglutide monotherapy Semaglutide 2.4mg alone (typical): 6 months: 20-30 lbs 12 months: 30-40 lbs 18 months: 35-45 lbs Average: 10-15% body weight CagriSema combination (typical): 6 months: 25-40 lbs 12 months: 40-60 lbs 18 months: 50-70+ lbs Average: 15-25% body weight Additional benefit: 50-75% more weight loss with combination Example: 240 lb person Semaglutide alone: Lose 24-36 lbs 204-216 lbs CagriSema combo: Lose 36-60 lbs 180-204 lbs Clinically significant difference See our peptides before and after results and how long do peptides take to work
Clinical Trial Results Researchers Watch Earlier phase 2 work found that once-weekly cagrilintide produced significant body-weight reductions in people with overweight or obesity and supported continued development of amylin-pathway medications
